HYD LLC. for Cancer Research and Drug Development, a technology based pharmaceutical company was established in 1992 to develop pharmaceuticals and consumer products that utilize a novel proprietary procedure, Deuterium Depletion for the treatment and prophylaxis of various types of cancer and other proliferative and neoplastic diseases. Deuterium Depletion opens new perspectives in cancer treatment and prevention offering a completely safe and non- invasive treatment modality.

In Hungary all research and development, including drug registration and other product development, based on the Deuterium Depletion technology is exclusively managed, organised and financed by HYD LLC. for Cancer Research and Drug Development.